Intervention not reported
Relapse · treating pulmonary TB
The intervention showed no clear difference in relapse (low certainty).
1 finding from 1 review
Intervention not reported
Death · treating pulmonary TB
The intervention showed no clear difference in death (moderate certainty).
1 finding from 1 review
Intervention not reported
Sputum smear or culture conversion at end of treatment · treating pulmonary TB
The intervention showed no clear difference in sputum smear or culture conversion at end of treatment (high certainty).
1 finding from 1 review
Intervention not reported
Serious adverse events · treating pulmonary TB
The intervention showed no clear difference in serious adverse events (moderate certainty).
1 finding from 1 review
Intervention not reported
Adverse events leading to discontinuation of therapy · treating pulmonary TB
The intervention showed no clear difference in adverse events leading to discontinuation of therapy (low certainty).
1 finding from 1 review
Intervention not reported
Combined endpoint of treatment failure, relapse, or death** · treating pulmonary TB
1 finding from 1 review
ACT use (percentage of children under 5 years receiving ACT on the same day or following day of fever onset) · Patients seeking treatment for suspected uncomplicated malaria
1 finding from 1 review
ACT availability (percentage of outlets stocking ACTs for children under 5 years) · Patients seeking treatment for suspected uncomplicated malaria
1 finding from 1 review
no estimate extracted
1 study · 2 participants
High
ACT availability (percentage of outlets stocking at least one ACT for patients of any age) · Patients seeking treatment for suspected uncomplicated malaria
1 finding from 1 review
no estimate extracted
1 study · 1 participants
Very low
ACT price (change in ACT prices for children under 5 years)c · Patients seeking treatment for suspected uncomplicated malaria
1 finding from 1 review
no estimate extracted
1 study · 1 participants
High
ACT market share (volume of ACTs purchased as a proportion of all antimalarials purchased; all age groups) · Patients seeking treatment for suspected uncomplicated malaria
1 finding from 1 review
no estimate extracted
1 study · 2 participants
High
Use of older antimalarials (amodiaquine, sulphadoxine‐pyrimethamine; children under 5 years) · Patients seeking treatment for suspected uncomplicated malaria
1 finding from 1 review
no estimate extracted
1 study · 1 participants
High
Adverse effects (such as the number of people receiving ACTs who do not have malaria) · Patients seeking treatment for suspected uncomplicated malaria
1 finding from 1 review
ACT access (percentage of illness episodes treated with ACTs; all age groups) · Patients seeking treatment for suspected uncomplicated malaria
1 finding from 1 review
ACT targeting (percentage of ACT takers who are malaria positive; all age groups) · Patients seeking treatment for suspected uncomplicated malaria
1 finding from 1 review
Intervention not reported
Exacerbations requiring oral corticosteroids 48 weeks · adults with asthma
The intervention showed no clear difference in exacerbations requiring oral corticosteroids 48 weeks (moderate certainty).
1 finding from 1 review
Intervention not reported
Quality of life (AQLQ) · adults with asthma
1 finding from 1 review
Intervention not reported
Serious adverse events 49 weeks · adults with asthma
The intervention showed no clear difference in serious adverse events 49 weeks (low certainty).
1 finding from 1 review
Intervention not reported
Exacerbations requiring hospital admission 49 weeks · adults with asthma
The intervention showed no clear difference in exacerbations requiring hospital admission 49 weeks (low certainty).
1 finding from 1 review
Intervention not reported
Lung function (change in trough FEV1 L) · adults with asthma
1 finding from 1 review